Approved indications: Mirabegron is approved for overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency, and for neurogenic detrusor overactivity (NDO) in pediatric patients 3 years and older who weigh at least 35 kg.

Off-label uses (evidence limited):

• Management of overactive bladder symptoms in adults with neurogenic bladder (such as from spinal cord injury or spina bifida), based mainly on small clinical studies.
• Treatment of OAB symptoms in men with benign prostatic hyperplasia (BPH) who are already receiving an alpha-blocker, where trials show added benefit with acceptable safety.

Efficacy expectations: Many patients begin to notice fewer urgency episodes and bathroom trips within 2 to 8 weeks; clinical studies show, on average, about 1 to 2 fewer incontinence episodes and 1 to 2 fewer urinations per day compared with baseline, and mirabegron provides symptom control similar to antimuscarinic bladder drugs but with less dry mouth and constipation, though it may raise blood pressure modestly.

Typical adult dosing (overactive bladder): The usual starting dose is 25 mg by mouth once daily; if needed and well tolerated after 4 to 8 weeks, the dose is increased to 50 mg once daily, which is the usual maximum dose.

Pediatric dosing (NDO, ≥3 years and ≥35 kg): For children 3 years and older who weigh at least 35 kg, the recommended starting dose is 25 mg once daily, which may be increased after 4 to 8 weeks to a maximum of 50 mg once daily if additional benefit is needed; younger or smaller children use weight-based mirabegron granules rather than tablets.

Dose limits in kidney or liver disease: In adults and children ≥35 kg with eGFR 30–89 mL/min/1.73 m² or mild hepatic impairment (Child-Pugh A), doses up to 50 mg once daily are allowed; in severe renal impairment (eGFR 15–29) or moderate hepatic impairment (Child-Pugh B), the maximum dose is 25 mg once daily; mirabegron is not recommended in end-stage renal disease or severe hepatic impairment.

How to take it: Swallow mirabegron extended-release tablets whole with water; do not crush, chew, or split them, because this can release the drug too quickly. Adults may take the tablets with or without food, while pediatric patients should take them with food; taking the dose at the same time each day helps maintain steady effect.

Missed dose: If a dose is missed and you remember within 12 hours, take it as soon as you remember; if more than 12 hours have passed, skip the missed dose and take the next dose at the usual time, and do not take extra tablets to make up for a missed dose.

Overdose: Taking more than prescribed can cause a fast heartbeat and increased blood pressure; in suspected overdose, seek emergency care or contact poison control immediately so that heart rhythm, blood pressure, and other vital signs can be monitored and treated supportively.

Common side effects:

• Mild increases in blood pressure or worsening of preexisting hypertension.
• Nasopharyngitis (cold-like symptoms), urinary tract infection, headache, constipation, and upper respiratory or other common infections.
• Less commonly, dizziness, fast heartbeat (tachycardia), diarrhea, fatigue, and abdominal pain; these usually appear in the first weeks and are often mild to moderate.

Serious or rare adverse effects (seek immediate care):

• Marked rise in blood pressure with severe headache, chest pain, shortness of breath, or neurologic symptoms.
• Inability to urinate, very weak urine stream, or painful difficulty passing urine (possible urinary retention).
• Severe allergic reactions or angioedema with swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, or widespread rash or hives.
• Irregular heartbeat, palpitations, or fainting.

Warnings and precautions: Mirabegron can increase blood pressure and is not recommended in patients with severe uncontrolled hypertension; dose limits apply in severe kidney impairment (eGFR 15–29 mL/min/1.73 m²) and moderate liver impairment (Child-Pugh B), and use is not recommended in end-stage renal disease or severe hepatic impairment. Caution is needed in people with bladder outlet obstruction or those taking antimuscarinic overactive bladder drugs, because urinary retention risk is higher, and in pregnancy and breastfeeding the drug is used only when potential benefits clearly outweigh the limited but potential risks.

Age-related considerations: Mirabegron is approved for adults with OAB and for children aged 3 years and older who weigh at least 35 kg with NDO; older adults generally tolerate it well but may be more sensitive to blood pressure increases and urinary retention and should be monitored.

Safety compared with other OAB drugs: Compared with antimuscarinic agents (such as oxybutynin or tolterodine), mirabegron tends to cause much less dry mouth, constipation, and cognitive side effects, but it may raise blood pressure slightly more and can modestly increase heart rate, so cardiovascular monitoring is important in at-risk patients.

Reporting and safety updates: In the United States, patients and clinicians can report side effects to FDA MedWatch (by phone or online), and the FDA website provides up-to-date drug safety communications; adverse events can also be reported to the product manufacturer.

Prescription and OTC drug interactions:

• Mirabegron moderately inhibits the enzyme CYP2D6 and can increase blood levels of drugs such as metoprolol, desipramine and other tricyclic antidepressants, certain antipsychotics, and class 1C antiarrhythmics (e.g., flecainide, propafenone); these may require dose adjustment and closer monitoring.
• It can increase levels of digoxin, so digoxin is usually started at a low dose and blood levels checked after starting or changing mirabegron.
• Use caution with other medicines that raise blood pressure or heart rate, as additive effects may occur.
• When combined with antimuscarinic bladder drugs (such as solifenacin or oxybutynin), symptom control may improve but the risk of urinary retention and dry mouth increases, so clinical monitoring is needed.

Food, alcohol, and supplements: Food does not significantly change absorption of mirabegron tablets, so adults may take them with or without meals; no specific food or herbal interactions are well established, but all over-the-counter medicines, supplements, and vitamins should be reviewed with a clinician or pharmacist, and alcohol should be used cautiously because it can contribute to dizziness or blood pressure changes.

Conditions requiring caution or avoidance:

• Severe uncontrolled hypertension (approximately systolic ≥180 mm Hg or diastolic ≥110 mm Hg) – mirabegron is not recommended.
• End-stage renal disease or severe hepatic impairment – use is not recommended.
• Bladder outlet obstruction, prior urinary retention, or concurrent OAB medications – monitor for difficulty urinating or rising post-void residual volume.
• History of arrhythmias, prolonged QT interval, or use of QT-prolonging drugs – consider ECG and closer monitoring, particularly at higher exposures.
• Pregnancy and breastfeeding – limited human data mean the drug should be used only when benefits clearly outweigh potential risks, after discussion with a healthcare professional.

Monitoring: Blood pressure should be checked periodically in all patients, especially those with hypertension or cardiovascular disease; clinicians may also monitor heart rate, post-void residual urine volume, and kidney or liver function in patients with organ impairment or taking interacting medications.

Q: What is mirabegron used for?
A: Mirabegron is used to treat overactive bladder symptoms in adults, such as sudden strong urges to urinate, frequent urination, and leakage accidents, and to treat neurogenic detrusor overactivity (a nerve-related bladder problem) in certain children 3 years and older who weigh at least 35 kg.

Q: How long does it take for mirabegron to start working?
A: Some people notice improvement in urgency and how often they urinate within 1 to 2 weeks, but it often takes 4 to 8 weeks of daily treatment to see the full benefit.

Q: Can mirabegron tablets be split, crushed, or chewed?
A: No; mirabegron tablets are extended-release and must be swallowed whole with water, because breaking, crushing, or chewing them can release the medicine too quickly and increase side effects.

Q: Can I take mirabegron with other overactive bladder medicines?
A: Doctors sometimes combine mirabegron with antimuscarinic bladder drugs for extra symptom control, but this can increase the chance of urinary retention and other side effects, so such combinations should only be used under close medical supervision.

Q: Does mirabegron cause weight gain or sexual side effects?
A: Weight gain and sexual dysfunction are not typical side effects of mirabegron; the most commonly reported problems are increases in blood pressure, urinary tract infections, headache, constipation, and cold-like symptoms.

Q: Is mirabegron safe to use long term?
A: Clinical studies of up to at least one year suggest that mirabegron remains effective and generally well tolerated with long-term use, but regular follow-up visits are important to monitor blood pressure and urinary symptoms and adjust therapy if needed.

Storage: Store mirabegron extended-release tablets at room temperature (68°F to 77°F / 20°C to 25°C), in the original tightly closed bottle, away from excess heat, moisture, and direct light, and keep them out of the reach of children and pets.

Disposal: Do not flush unused tablets down the toilet or sink unless specifically instructed; instead, use a community drug take-back program when possible, or mix tablets (without crushing) with an undesirable substance in a sealed container before placing them in household trash, and ask your pharmacist or local waste authority for any additional disposal recommendations.